ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective treatments with significant health benefits, but affordability and long-term management are still unresolved.
Formulary Watch
Latest News
All News
Advertisement
Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.
Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.
In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with nutrition and lifestyle support, as well as prescriptions for medications.
Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of 2025, with diabetes submissions to follow in 2026.
A new Business Group on Health survey finds that nearly a quarter of all employer healthcare spending (24%) went to pharmacy expenses in 2024, and employers forecast an 11% to 12% increase in pharmacy costs heading into 2026.
Dawnzera (donidalorsen) will be available in a few days with a list price of $57,462 per dose
The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.
The FDA has granted priority review of the sNDA and assigned a goal date of Dec. 20, 2025, for Imcivree to treat patients with acquired hypothalamic obesity, which is caused by an abnormality of the hypothalamus.
A new study finds Medicare beneficiaries are facing higher deductibles and cost-sharing requirements following changes implemented by health plans as a result of the Inflation Reduction Act.
Advertisement
Tonmya is the first new fibromyalgia treatment approved by the FDA in more than 15 years, providing symptom relief for at least 30% of patients when compared to placebo, according to clinical trial results.
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ongoing study aims to confirm the benefits.
Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ongoing clinical studies showing symptom relief for up to two years.
To help Medicare plans better manage members with high drug expenses, Prime Therapeutics has launched an AI-driven tool to help plans identify members likely to experience increases in pharmacy costs.
Managing specialty and cancer drugs, as well as the GLP-1 therapies, tops the list of priorities this year and next, according to a survey by the International Foundation of Employee Benefit Plans.
Pharmacists and prescribers express ongoing concern about medication prior authorization struggles, but most are willing to adopt new technologies to ease the burden, according to a recent Surescripts survey.
Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis (NCFB).
Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this debilitating condition.
Modeyso is the first drug to treat patients with diffuse midline glioma with an H3 K27M mutation, an ultra-rare and aggressive brain tumor.
Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing reports indicated there is a risk of neurologic and cardiac events in people over the age of 60.
The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.
Sarepta continues to work with regulators to complete the safety label update for Elevidys, and they are discussing an approach for risk mitigation for non-ambulatory patients.
Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Health policy researcher Geoffrey Joyce argues that only delinking compensation from the list price of a drug will lower drug spending.
Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
4
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
5
